Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05600894 | RECRUITING | Chronic Myelomonocytic Leukemia

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Sponsor:

National Cancer Institute (NCI)

Brief Summary:

This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts. Blasts are immature blood cells. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. The combination of ASTX727 and venetoclax may be more effective in reducing the cancer signs and symptoms in patients with CMML, or MDS/MPN with excess blasts.

Condition or disease

Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome

Myelodysplastic Syndrome With Excess Blasts

Myelodysplastic/Myeloproliferative Neoplasm

Myeloproliferative Neoplasm

Intervention/treatment

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Decitabine and Cedazuridine

Venetoclax

Phase

PHASE2

Detailed Description:

PRIMARY OBJECTIVE: I. To evaluate the complete remission rates of ASTX727 and ASTX727 plus venetoclax in subjects with CMML and non-CMML MDS/MPN with excess (\>= 5%) blasts. SECONDARY OBJECTIVES: I. To evaluate the overall response rate (complete response \[CR\] + partial response \[PR\] + marrow response with erythroid response) of ASTX727 versus ASTX727 + venetoclax in this patient population. II. To determine the overall survival, progression-free survival, allogeneic hematopoietic stem cell transplantation rate, clearance of the malignant clone, clonality at time of hematologic remission, number of red cell and platelet transfusions required and toxicity of ASTX727 versus ASTX727 + venetoclax. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I (COMBINATION THERAPY): Patients receive ASTX727 orally (PO) once daily (QD) on days 1-5 of each cycle and venetoclax PO QD on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy and aspiration and collection of blood samples throughout the study and undergo buccal swab sample collection at screening. ARM II (MONO THERAPY): Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not have response to treatment may cross over to Arm I. Patients also undergo bone marrow biopsy and aspiration and collection of blood samples throughout the study and undergo buccal swab sample collection at screening. After completion of study treatment, patients are followed up every 6 months for 5 years or until death, whichever occurs first.

Study Type : INTERVENTIONAL
Estimated Enrollment : 132 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Venetoclax In Combination With ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial
Actual Study Start Date : 2023-06-27
Estimated Primary Completion Date : 2025-08-31
Estimated Study Completion Date : 2025-08-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * A diagnosis of an MDS/MPN "overlap" syndrome with \>= 5% marrow blasts (including monocytic blast equivalent in case of CMML). Hydroxyurea may be used to control counts up until the start of therapy
  • * White blood cell (WBC) \< 25,000/mm\^3. Treatment with hydroxyurea is permitted to lower the WBC to reach this criterion
  • * Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of ASTX727 in combination with venetoclax in patients \< 18 years of age, children are excluded from this study
  • * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
  • * Total bilirubin =\< 1.5 x upper limit of normal (ULN) (unless considered due to Gilbert's syndrome)
  • * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3.0 x institutional ULN OR =\< 5.0 x institutional ULN for patients with liver metastases
  • * Glomerular filtration rate (GFR) \>= 30 mL/min/1.73 m\^2
  • * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Hormonal therapy for prior or concurrent malignancy is allowed
  • * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
  • * Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) and/or family member available will also be eligible
  • * Ability to swallow pills
Exclusion Criteria
  • * Patients with need for emergent disease-directed therapy excluding hydroxyurea
  • * More than one cycle of previous MDS/MPN-directed therapy, or MDS-directed therapy including lenalidomide and hypomethylating agent (HMAs) such as decitabine or azacitidine, excluding hydroxyurea. Prior use of erythropoietin stimulating agents (ESA) and thrombopoietic agents is allowed, but must be discontinued 4 weeks prior to study treatment
  • * Patients currently or previously receiving an investigational agent or device within 4 weeks of the first dose of treatment
  • * Patients with symptomatic uncontrolled central nervous system (CNS) disease. Imaging to confirm the absence of brain metastases is not required. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days
  • * Patients who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit within 3 days prior to the initiation of study treatment and are unwilling to discontinue consumption of these throughout the receipt of study drug
  • * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ASTX727 or venetoclax
  • * Patients with uncontrolled intercurrent illness (e.g. requiring intravenous therapy) at the discretion of the investigator
  • * Pregnant women are excluded from this study because venetoclax and ASTX727 have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax. These potential risks may also apply to other agents used in this study. Patients must be post-menopausal or with evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1
  • * Post-menopausal is defined as
    • * Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments
    • * Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range for women under 50 years of age
    • * Radiation-induced oophorectomy with last menses \> 1 year ago
    • * Chemotherapy-induced menopause with \> 1 year interval since last menses
    • * Surgical sterilization (bilateral oophorectomy or hysterectomy)
    • * Women of child-bearing potential must agree to use adequate contraception (hormonal birth control or abstinence) prior to study entry and for the duration of study participation, and for 6 months following completion of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception (latex or synthetic condom or abstinence) prior to the study, for the duration of study participation, and 3 months after completion of venetoclax and ASTX727 administration
    • * Patients with any other medical condition for which the expected survival is below 12 months
    • * Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or assessment of the investigational regimen
    • * Patients with uncontrolled infection at the time of study entry
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Location Details

NCT05600894

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Arizona

Mayo Clinic Hospital in Arizona

Phoenix, Arizona, United States, 85054

RECRUITING

United States, California

UC Irvine Health Cancer Center-Newport

Costa Table, California, United States, 92627

RECRUITING

United States, California

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Irvine, California, United States, 92612

RECRUITING

United States, California

UCI Health Laguna Hills

Laguna Hills, California, United States, 92653

SUSPENDED

United States, California

Los Angeles General Medical Center

Los Angeles, California, United States, 90033

SUSPENDED

United States, California

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States, 90033

RECRUITING

United States, California

UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange, California, United States, 92868

RECRUITING

United States, California

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States, 95817

RECRUITING

United States, Connecticut

Yale University

New Haven, Connecticut, United States, 06520

RECRUITING

United States, Florida

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224-9980

RECRUITING

United States, Illinois

Northwestern University

Chicago, Illinois, United States, 60611

RECRUITING

United States, Illinois

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, United States, 60637

RECRUITING

United States, Illinois

UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, United States, 60451

RECRUITING

United States, Illinois

University of Chicago Medicine-Orland Park

Orland Park, Illinois, United States, 60462

RECRUITING

United States, Kansas

University of Kansas Cancer Center

Kansas City, Kansas, United States, 66160

RECRUITING

United States, Kansas

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, United States, 66205

RECRUITING

United States, Maryland

University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, United States, 21201

RECRUITING

United States, Maryland

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, United States, 21287

RECRUITING

United States, Massachusetts

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

RECRUITING

United States, New York

Montefiore Medical Center-Einstein Campus

Bronx, New York, United States, 10461

RECRUITING

United States, New York

Montefiore Medical Center-Weiler Hospital

Bronx, New York, United States, 10461

RECRUITING

United States, New York

Montefiore Medical Center - Moses Campus

Bronx, New York, United States, 10467

RECRUITING

United States, New York

NYP/Weill Cornell Medical Center

New York, New York, United States, 10065

RECRUITING

United States, North Carolina

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States, 27599

RECRUITING

United States, North Carolina

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States, 27157

RECRUITING

United States, Ohio

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, United States, 45219

RECRUITING

United States, Ohio

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States, 43210

RECRUITING

United States, Ohio

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, United States, 45069

RECRUITING

United States, Oklahola

University of Oklahoma Health Sciences Center

Ololama City, Okholohan, United States, 73104

RECRUITING

United States, Pennsylvania

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, United States, 15232

RECRUITING

United States, Utah

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, United States, 84112

RECRUITING

United States, Virginia

University of Virginia Cancer Center

Charlottesville, Virginia, United States, 22908

RECRUITING

United States, Virginia

Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, United States, 23298

RECRUITING

Canada, Ontario

University Health Network-Princess Margaret Hospital

Toronto, Ontario, Canada, M5G 2M9